跳至主要内容
临床试验/NCT01865565
NCT01865565已完成不适用

A Trial for Surgical Treatment in Patients With Initially Locally Unresectable Advanced GIST Without Metastasis During Therapy With Imatinib

Chang Gung Memorial Hospital1 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2013年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
51
试验地点
1
主要终点
progression free survival

研究概览

简要总结

Gastrointestinal stromal tumors (GISTs) are a form of sarcoma and the most common sarcoma tumors of the gastrointestinal tract. The limited clinical experience suggests that GIST patients may benefit from neo-adjuvant therapy from primary GIST. This is a prospective, multicenter, open, observational study in evaluation of safety and efficacy of imatinib compared with that of historical data for locally unresectable advanced GIST without metastasis. The study will include an up to 28-day screening period, followed by receiving imatinib mesylate (400 mg/day) for at least 6-12 months and followed up for 3 years after surgery.

详细描述

Primary Objective

  • To observe the safety of imatinib compared with that of historical data for locally unresectable advanced GIST without metastasis.

Secondary Objective

  • Progression-free survival (PFS) in resected patients during follow up
  • R0 resection rate
  • objective response rate, tumor shrinkage rate
  • Correlation of mutation status with response
  • Correlation of PK with response
  • Surgical morbidity and mortality and safety follow up
  • Quality of life
  • Overall survival (OS)

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

progression free survival

时间窗: five years

Evidence of measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines with CT scan.

次要结局

  • R0 resection rate(three years)
  • Objective response rate, tumor shrinkage rate(three years)
  • Surgical morbidity and mortality and safety follow up(five years)
  • Correlation of PK with response(three years)
  • Overall survival (OS)(five years)

研究者

发起方
Chang Gung Memorial Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Chun-Nan Yeh

MD, Associate Professor, Dept. of General Surgery.

Chang Gung Memorial Hospital

研究点 (1)

Loading locations...

相似试验